Oral Pyrophosphate Delivery via Enteric Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for soft tissue calcification disorders, such as pseudoxanthoma elasticum and generalized arterial calcification of infancy, are ineffective due to the belief that inorganic pyrophosphate (PPi) is ineffective when administered orally, as it is thought to be hydrolytically destroyed in the gut, limiting long-term treatment options for these conditions.
Innovation Solution
Oral administration of inorganic pyrophosphate (PPi) is effective in preventing and treating soft tissue calcification disorders by achieving a transient increase in plasma PPi levels, which can inhibit calcification, as demonstrated in mouse models and human studies, allowing for long-term management of these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If inorganic pyrophosphate (PPi) is administered orally, then treatment convenience and compliance are improved, but PPi is hydrolytically destroyed in the gut, rendering it ineffective
Solution Approach 1:
The patent uses enteric-coated tablets as an intermediary delivery system that protects PPi from hydrolytic destruction in the gastrointestinal tract. The enteric coating acts as a mediator that allows PPi to survive passage through the gut and be absorbed intact into the bloodstream, thereby maintaining both oral administration convenience and treatment effectiveness.
2Reliability
If intravenous PPi administration is used, then treatment effectiveness is maintained, but treatment complexity and burden increase
Solution Approach 1:
The patent extracts the problematic element (the need for intravenous administration) by developing an oral formulation that overcomes the previously insurmountable barrier of gastrointestinal hydrolysis. This eliminates the complexity of IV equipment and procedures while maintaining the therapeutic effectiveness of PPi through enteric-protected oral delivery.
3Ease of operation
If oral PPi is administered without enteric coating, then administration simplicity is improved, but PPi is destroyed before absorption
Solution Approach 1:
The enteric coating is applied in advance to the PPi tablets before administration, creating a protective barrier that prevents premature hydrolysis in the stomach and upper intestine. This preliminary protective action ensures that PPi remains intact until it reaches the lower intestine where absorption occurs, thereby maintaining both administration simplicity and adequate PPi absorption.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Oral PPi administration attenuates calcification in soft tissues, including vascular calcification, and is safe for long-term use, providing a feasible treatment option for hereditary and life-long conditions characterized by low plasma PPi levels, without adverse effects on bone calcification or inducing osteomalacia.
Implementation Method 1
Pyrophosphate is a potent inhibitor of hydroxyapatite formation, and, under normal conditions, functions to inhibit soft tissue calcification
Implementation Method 2
released ATP is rapidly converted into AMP and PPi by the ectoenzyme ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1)
Data Source
AI summary
The invention is concerned with use of oral inorganic pyrophosphate for preventing and/or reducing tissue calcification, particularly soft tissue calcification, and/or diseases or disorders characterized by low plasma PPi levels, as, e.g., occurs in chronic kidney disease (CKD), end-stage renal disease (ESRD), generalized arterial calcification of infancy (GACI), Pseudoxanthoma elasticum (PXE), Arterial Calcification Due to Deficiency of CD73 (ACDC), Ehlers-Danlos syndrome, arteriosclerosis obliterans, venous calcifications, crystal deposition disorders, calcification resulting from neurological disorders, calcinosis universalis, calcinosis circumscripta, scleroderma, dermatomyositis, systemic lupus erythematosus, hyperparathyroidism, neoplasms, milk-alkali syndrome, hypervitaminosis D, tumoral calcinosis, hypophosphatemic rickets, ossification of the posterior longitudinal ligament of the spine, myocardial ischemia, joint calcification, heterotropic ossification of traumatized muscle, angioid streaks, diabetes mellitus type II, cardiovascular disorder, or atherosclerosis.